Intramuscular recombinant Erwinia asparaginase active, safe in leukemia, lymphoma subsets

A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.
Results of the Children’s Oncology Group AALL1931 study — presented at ASCO Annual Meeting — showed a positive benefit-risk profile of the agent (Rylaze, Jazz Pharmaceuticals) when administered in a 3-day-a-week dosing schedule.
The safety profile appeared consistent with that of other asparaginases.
Luke Maese, DO, associate professor of

A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.
Results of the Children’s Oncology Group AALL1931 study — presented at ASCO Annual Meeting — showed a positive benefit-risk profile of the agent (Rylaze, Jazz Pharmaceuticals) when administered in a 3-day-a-week dosing schedule.
The safety profile appeared consistent with that of other asparaginases.
Luke Maese, DO, associate professor of